Bordetella pertussis PCR positivity, following onset of illness in children under 5 years of age
DOI:
https://doi.org/10.33321/cdi.2007.31.17Keywords:
Bordetella pertussis, disease management, epidemiology, laboratory testing, PCR testingAbstract
Erratum published in Commun Dis Intell 2007;31 (4):448. There was an inconsistency in the figure heading and the X axis title for Figure 4. The corrected figure is reproduced in the attached Erratum. See DOI: 10.33321/cdi-2007-31-51
Bordetella pertussis is a significant cause of respiratory illness and an ongoing public health problem. Pertussis polymerase chain reaction (PCR) testing has been widely utilised since 2001, especially in infants. Uncertainty exists as to how long PCR remains positive following symptom onset. Further information on the time frame for pertussis PCR testing would assist diagnosis, epidemiological research and disease control. The Brisbane Southside Population Health Unit (BSPHU) conducted a retrospective analysis of enhanced surveillance data from pertussis notifications between January 2001 and December 2005, in children less than 5 years of age, in the BSPHU reporting area with the aim to determine the possible range of duration of Bordetella pertussis PCR, from symptom onset for this age group. Of 1,826 pertussis notifications to BSPHU between January 2001 and December 2005, 155 (8.5%) were children under 5 years of age, with 115 pertussis PCR positive results. Analysis indicated a range of PCR positivity from day one to day 31 from the onset of catarrhal symptoms with most (84%) being within 21 days from onset of catarrhal symptoms. The range of PCR positivity following onset of paroxysmal cough was from day one to day 38 with most (89%) being within 14 days from the onset of paroxysmal cough. This review of pertussis PCR data in young children showed that PCR positive results generally mirrored the understood length of infectivity with regard to both catarrhal symptoms and paroxysmal cough; namely that PCR positive results were obtained at least 21 days following onset of catarrhal symptoms and at least 14 days following onset of paroxysmal cough. Commun Dis Intell 2007;31:202–205.
Downloads
References
Centers for Disease Control and Prevention. Recommended antimicrobial agents treatment and postexposure prophylaxis of pertussis. MMWR Morb Mortal Wkly Rep 2005;54;14:1–16.
Wirsing von Konig CH, et al. Pertussis of adults and infants. Lancet Inf Dis 2002;2:744–750.
Halperin SA. (editorial) Pertussis – a disease and vaccine for all ages. NEJM 2005;353;15:1615–1617.
Bisgard KM, Pascual FB, Ehresmann RN, et al. Infant pertussis who was the source? Pediatr Infect Dis J 2004;23:985–989.
Lievano FA, Reynolds MA, Waring AL et al. Issues associated with and recommendations for using PCR to detect outbreaks of pertussis. J Clin Micrbiol 2002;40:2801–2805.
Kosters K, Reischall U, Schmetz J, Riffelmann M, et al. Real-time light cycler PCR for detection and discrimination of Bordetella pertussis and Bordetella parapertussis. J Clin Micrbiol 2002;40:1719–1722.
Farrell DJ, McKeon M, Daggard G, Loeddelholz MJ, et al. Rapid-cycle PCR method to detect Bordetella pertussis that fulfils all consensus recommendations for use of PCR in diagnosis of pertussis. J Clin Micrbiol 2000;38:4499–4502.
Horby P, Macintyre CR, McIntyre PB, et al. A boarding school outbreak of pertussis in adolescents: value of laboratory diagnostic methods. Epidemiol Infect 2005;133:229–236.
Queensland Health Guidelines for the Control of Communicable Diseases in the Community. 3rd Edition 2005, Queensland Government, Queensland Health.
Halperin SA. The control of pertussis – 2007 and beyond. NEJM 2007;356:110–113.
Cherry JD. The epidemiology of pertussis :a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Paediatrics 2005;115:1422–1427.
Downloads
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2007 Communicable Diseases Intelligence

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
